WAY vs NVCR

For growth investors, Waystar Holding Corp.

(WAY) is the stronger pick with 16. 5% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Waystar Holding Corp. (WAY) offers the better valuation at 30. 7x trailing P/E (11. 4x forward), making it the more compelling value choice. Analysts rate Waystar Holding Corp. (WAY) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Waystar Holding Corp.

(WAY) delivered a total return of -9. 4%, compared to -91. 9% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NVCR returned +62. 1% versus WAY's -9. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Waystar Holding Corp.

(WAY) is the lower-risk stock at 0. 84β versus NovoCure Limited's 2. 21β — meaning NVCR is approximately 163% more volatile than WAY relative to the S&P 500. On balance sheet safety, Waystar Holding Corp. (WAY) carries a lower debt/equity ratio of 39% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Waystar Holding Corp.

(WAY) is pulling ahead at 16. 5% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Waystar Holding Corp. grew EPS 569. 2% year-over-year, compared to 21. 8% for NovoCure Limited. Over a 3-year CAGR, WAY leads at 16. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Waystar Holding Corp.

(WAY) is the more profitable company, earning 10. 2% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 10. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WAY leads at 24. 2% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for WAY: 90.

0% to $35. 62.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Waystar Holding Corp.

(WAY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 84)). NovoCure Limited (NVCR) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (WAY: -9. 4%, NVCR: +62. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (WAY (Technology) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: WAY is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.